MARX Biotech Co., Ltd.
MARX Biotech Co., Ltd. engages in the online retail of men's health food and cosmeceutical products. The company was founded in 2015 and is based in New Taipei City, Taiwan.
MARX Biotech Co., Ltd. (7731) - Total Assets
Latest total assets as of June 2025: NT$733.01 Million TWD
Based on the latest financial reports, MARX Biotech Co., Ltd. (7731) holds total assets worth NT$733.01 Million TWD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
MARX Biotech Co., Ltd. - Total Assets Trend (2021–2024)
This chart illustrates how MARX Biotech Co., Ltd.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
MARX Biotech Co., Ltd. - Asset Composition Analysis
Current Asset Composition (December 2024)
MARX Biotech Co., Ltd.'s total assets of NT$733.01 Million consist of 55.7% current assets and 44.3% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 10.2% |
| Accounts Receivable | NT$121.73 Million | 16.7% |
| Inventory | NT$164.31 Million | 22.5% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$65.36 Million | 8.9% |
| Goodwill | NT$26.25 Million | 3.6% |
Asset Composition Trend (2021–2024)
This chart illustrates how MARX Biotech Co., Ltd.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: MARX Biotech Co., Ltd.'s current assets represent 55.7% of total assets in 2024, a decrease from 97.0% in 2021.
- Cash Position: Cash and equivalents constituted 10.2% of total assets in 2024, down from 17.7% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 11.0% of total assets, an increase from 0.0% in 2021.
- Asset Diversification: The largest asset category is inventory at 22.5% of total assets.
MARX Biotech Co., Ltd. Competitors by Total Assets
Key competitors of MARX Biotech Co., Ltd. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Cachet Pharmaceutical Co Ltd
SHE:002462
|
China | CN¥12.68 Billion |
|
Yunnan Hongxiang Yixintang
SHE:002727
|
China | CN¥15.84 Billion |
|
Luyan Pharma Co Ltd
SHE:002788
|
China | CN¥13.04 Billion |
|
Ji Yao Holding Group Co Ltd
SHE:300108
|
China | CN¥1.43 Billion |
|
Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. Ltd.
SHE:300937
|
China | CN¥1.75 Billion |
|
ShuYu Civilian Pharmacy Corp. Ltd.
SHE:301017
|
China | CN¥9.84 Billion |
|
Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd
SHE:301126
|
China | CN¥6.56 Billion |
|
Anhui Huaren Health Pharmaceutical Co. Ltd. Cl A
SHE:301408
|
China | CN¥5.26 Billion |
MARX Biotech Co., Ltd. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - MARX Biotech Co., Ltd. generates 0.85x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - MARX Biotech Co., Ltd. is currently not profitable relative to its asset base.
MARX Biotech Co., Ltd. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.16 | 2.13 | 2.31 |
| Quick Ratio | 0.43 | 1.57 | 2.03 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$53.98 Million | NT$ 185.71 Million | NT$ 54.56 Million |
MARX Biotech Co., Ltd. - Advanced Valuation Insights
This section examines the relationship between MARX Biotech Co., Ltd.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 13.16 |
| Latest Market Cap to Assets Ratio | 0.07 |
| Asset Growth Rate (YoY) | 85.2% |
| Total Assets | NT$731.20 Million |
| Market Capitalization | $50.74 Million USD |
Valuation Analysis
Below Book Valuation: The market values MARX Biotech Co., Ltd.'s assets below their book value (0.07 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: MARX Biotech Co., Ltd.'s assets grew by 85.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for MARX Biotech Co., Ltd. (2021–2024)
The table below shows the annual total assets of MARX Biotech Co., Ltd. from 2021 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$731.20 Million | +85.18% |
| 2023-12-31 | NT$394.85 Million | +282.66% |
| 2022-12-31 | NT$103.19 Million | +13.30% |
| 2021-12-31 | NT$91.08 Million | -- |